ArriVent BioPharma (AVBP) Accounts Payables (2023 - 2026)
ArriVent BioPharma (AVBP) posted Accounts Payables of $8.7 million for Q1 2026, up 47.07% sequentially from $5.9 million in Q4 2025, and up 99.98% YoY from $4.4 million in Q1 2025.
ArriVent BioPharma (AVBP) Accounts Payables (2023 - 2026) Analysis & Trends
ArriVent BioPharma has reported Accounts Payables for 4 years, with the latest figure at $8.7 million in Q1 2026.
- Quarterly Accounts Payables rose 99.98% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (up 99.98% YoY) and the FY2025 annual result came in at $5.9 million, up 56.9% from the prior year.
- Accounts Payables rose to $8.7 million in Q1 2026 per AVBP's latest filing, from $5.9 million in the prior quarter.
- Over five years, Accounts Payables peaked at $8.7 million in Q1 2026 and troughed at $3.8 million in Q4 2024.
- A 4-year average of $5.0 million and a median of $4.4 million in 2023 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2024 and 2026: Accounts Payables declined 16.55% in 2024, then soared 99.98% in 2026.
- Over 4 years, Accounts Payables stood at $4.5 million in 2023, then decreased by 16.55% to $3.8 million in 2024, then jumped by 56.9% to $5.9 million in 2025, then jumped by 47.07% to $8.7 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $8.7 million, $5.9 million, and $5.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | ArriVent BioPharma | 1.43 Bn | 1.43 Bn | - | 2.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.22 Mn |
| Mar 31, 2026 | 8.73 Mn |
| Dec 31, 2025 | 5.93 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 4.06 Mn |
| Mar 31, 2025 | 4.36 Mn |
| Dec 31, 2024 | 3.78 Mn |
| Sep 30, 2024 | 4.65 Mn |
| Jun 30, 2024 | 3.81 Mn |
| Mar 31, 2024 | 4.10 Mn |
| Dec 31, 2023 | 4.53 Mn |